Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 10/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25544287 | 0.85 | PDE2A (0.33) | TLR9TLR8TLR7PDE2A | |
| SCHEMBL25544271 | 0.85 | HPGD (0.32) | PDE2A | |
| SCHEMBL25544269 | 0.84 | SLC9A1 (0.33) | PDE2A | |
| SCHEMBL23887752 | 0.84 | CNR1 (0.36) | TLR9TLR8TLR7 | |
| SCHEMBL25544712 | 0.82 | TLR9 (0.36) | TLR9TLR8TLR7IRAK4PDE2A | |
| SCHEMBL25544722 | 0.80 | ACHE (0.34) | IRAK4 | |
| SCHEMBL25544713 | 0.76 | PDE2A (0.37) | TLR9TLR8TLR7IRAK4FABP4 | |
| SCHEMBL23895975 | 0.72 | PIK3CA (0.40) | TLR9TLR8TLR7IRAK4FABP4 | |
| SCHEMBL23887776 | 0.71 | FFAR1 (0.37) | — | |
| SCHEMBL25544710 | 0.71 | PDE10A (0.38) | TLR9TLR8TLR7IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | TLR9 4766/4885TLR8 2667/4885TLR7 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.